1. Home
  2. SKYT vs XERS Comparison

SKYT vs XERS Comparison

Compare SKYT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYT
  • XERS
  • Stock Information
  • Founded
  • SKYT 1991
  • XERS 2005
  • Country
  • SKYT United States
  • XERS United States
  • Employees
  • SKYT N/A
  • XERS N/A
  • Industry
  • SKYT Semiconductors
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SKYT Technology
  • XERS Health Care
  • Exchange
  • SKYT Nasdaq
  • XERS Nasdaq
  • Market Cap
  • SKYT 426.4M
  • XERS 444.0M
  • IPO Year
  • SKYT 2021
  • XERS 2018
  • Fundamental
  • Price
  • SKYT $8.68
  • XERS $3.10
  • Analyst Decision
  • SKYT Strong Buy
  • XERS Buy
  • Analyst Count
  • SKYT 4
  • XERS 3
  • Target Price
  • SKYT $12.75
  • XERS $4.87
  • AVG Volume (30 Days)
  • SKYT 419.6K
  • XERS 1.9M
  • Earning Date
  • SKYT 11-07-2024
  • XERS 11-08-2024
  • Dividend Yield
  • SKYT N/A
  • XERS N/A
  • EPS Growth
  • SKYT N/A
  • XERS N/A
  • EPS
  • SKYT N/A
  • XERS N/A
  • Revenue
  • SKYT $345,935,000.00
  • XERS $187,361,000.00
  • Revenue This Year
  • SKYT $22.45
  • XERS $20.35
  • Revenue Next Year
  • SKYT N/A
  • XERS $16.14
  • P/E Ratio
  • SKYT N/A
  • XERS N/A
  • Revenue Growth
  • SKYT 26.89
  • XERS 22.72
  • 52 Week Low
  • SKYT $5.63
  • XERS $1.69
  • 52 Week High
  • SKYT $12.97
  • XERS $3.64
  • Technical
  • Relative Strength Index (RSI)
  • SKYT 42.32
  • XERS 49.79
  • Support Level
  • SKYT $7.81
  • XERS $2.82
  • Resistance Level
  • SKYT $8.98
  • XERS $3.33
  • Average True Range (ATR)
  • SKYT 0.58
  • XERS 0.18
  • MACD
  • SKYT -0.13
  • XERS -0.04
  • Stochastic Oscillator
  • SKYT 18.68
  • XERS 33.54

About SKYT SkyWater Technology Inc.

SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Share on Social Networks: